HK1076711A1 - Chimeric cd154 - Google Patents

Chimeric cd154

Info

Publication number
HK1076711A1
HK1076711A1 HK05107749.4A HK05107749A HK1076711A1 HK 1076711 A1 HK1076711 A1 HK 1076711A1 HK 05107749 A HK05107749 A HK 05107749A HK 1076711 A1 HK1076711 A1 HK 1076711A1
Authority
HK
Hong Kong
Prior art keywords
chimeric
human
sequence encoding
vector
polynucleotide sequence
Prior art date
Application number
HK05107749.4A
Other languages
English (en)
Inventor
Charles E Prussak
Thomas J Kipps
Mark J Cantwell
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1076711A1 publication Critical patent/HK1076711A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
HK05107749.4A 2002-05-23 2005-09-02 Chimeric cd154 HK1076711A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/154,759 US7495090B2 (en) 2002-05-23 2002-05-23 Nucleic acids encoding chimeric CD154 polypeptides
PCT/US2003/016305 WO2003099340A1 (en) 2002-05-23 2003-05-23 Novel chimeric cd154

Publications (1)

Publication Number Publication Date
HK1076711A1 true HK1076711A1 (en) 2006-01-27

Family

ID=29548954

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05107749.4A HK1076711A1 (en) 2002-05-23 2005-09-02 Chimeric cd154

Country Status (14)

Country Link
US (3) US7495090B2 (de)
EP (1) EP1509253B1 (de)
JP (1) JP4454493B2 (de)
CN (1) CN100482283C (de)
AT (1) ATE458058T1 (de)
AU (1) AU2003231819B2 (de)
CA (1) CA2486918C (de)
DE (1) DE60331307D1 (de)
DK (1) DK1509253T3 (de)
ES (1) ES2341331T3 (de)
HK (1) HK1076711A1 (de)
IL (1) IL165347A (de)
PT (1) PT1509253E (de)
WO (1) WO2003099340A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
CN101522210B (zh) 2006-09-18 2017-03-22 阿肯色大学评议会 增强免疫应答的组合物和方法
JP2010511731A (ja) * 2006-12-05 2010-04-15 メムジェン エルエルシー キメラｉｓｆ３５を利用した化学療法剤に対する癌感受性増強方法
NZ585776A (en) * 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PL2214701T3 (pl) * 2007-11-01 2017-01-31 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
UA110024C2 (uk) 2010-01-21 2015-11-10 Вакцинний вектор і спосіб посилення імунної відповіді
KR102007132B1 (ko) 2010-06-09 2019-08-05 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
US9562088B2 (en) 2010-10-19 2017-02-07 The Regents Of The University Of Colorado, A Body Corporate Pegylated CD154 peptides and methods of inhibiting CD40 interacations with CD154
WO2014132142A2 (en) * 2013-01-30 2014-09-04 King Abdullah University Of Science And Technology Method of detaching adherent cells for flow cytometry
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EP2968423A4 (de) 2013-03-15 2016-11-09 Univ Arkansas Zusammensetzungen und verfahren zur verstärkung der immunreaktionen gegen enterale pathogene
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017024146A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
US20180244750A1 (en) * 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
LT3370733T (lt) 2015-11-02 2021-10-25 Board Of Regents, The University Of Texas System Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
CN110650745A (zh) * 2016-12-21 2020-01-03 曼珍有限责任公司 武装复制型溶瘤腺病毒
US20200353044A1 (en) * 2017-04-12 2020-11-12 Memgen, Llc Methods of cd40 and toll like receptor immune activation
SG11202006494VA (en) * 2018-01-05 2020-08-28 Op T Llc Therapeutic peptides and methods for treating autoimmune related disease
MX2020013901A (es) * 2018-06-19 2021-05-27 H Lee Moffitt Cancer Ct & Res Virus oncolítico o antígeno que presenta terapia contra el cáncer mediada por células usando interferón tipo i y lingado de cd40.
SG11202109225WA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Cd40l compositions and methods for tunable regulation
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US20220259284A1 (en) 2019-06-12 2022-08-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
WO2022056302A1 (en) * 2020-09-11 2022-03-17 Memgen, Inc. Enhancing immunity using chimeric cd40 ligand and coronavirus vaccine
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US22017A (en) * 1858-11-09 Pen-fountain
US2002A (en) * 1841-03-12 Tor and planter for plowing
ATE87007T1 (de) 1987-05-29 1993-04-15 Sagami Chem Res Fusionsprotein, enthaltend lymphotoxin.
EP0750037A3 (de) 1989-08-16 1997-01-15 Cetus Oncology Corporation TNF-Konvertas und Verfahren zum Messen der TNF-Konvertashemmung
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
DK0822199T3 (da) 1991-10-25 2004-12-27 Amgen Inc N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
CA2142860A1 (en) 1992-08-21 1994-03-03 Gregorio Aversa Human interleukin-13
CA2153806C (en) 1993-01-22 2005-11-08 Melanie K. Spriggs Detection and treatment of mutations in a cd40 ligand gene
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
WO1995018819A1 (en) 1994-01-07 1995-07-13 Immunex Corporation Ligand that binds fas antigen
MX9605088A (es) * 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
CA2304130C (en) 1997-09-17 2008-10-28 Mochida Pharmaceutical Co., Ltd. Novel fas ligand derivative
US6451759B1 (en) * 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
WO2001078769A2 (en) 2000-04-12 2001-10-25 University Of South Florida Regulation of systemic immune responses utilizing soluble cd40
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
AU2003231819A1 (en) 2003-12-12
EP1509253A4 (de) 2005-12-21
DE60331307D1 (de) 2010-04-01
US20030220473A1 (en) 2003-11-27
US7928213B2 (en) 2011-04-19
ES2341331T3 (es) 2010-06-18
JP4454493B2 (ja) 2010-04-21
AU2003231819B2 (en) 2008-07-10
PT1509253E (pt) 2010-05-21
CN100482283C (zh) 2009-04-29
WO2003099340A1 (en) 2003-12-04
EP1509253A1 (de) 2005-03-02
IL165347A (en) 2012-05-31
US8138310B2 (en) 2012-03-20
CA2486918C (en) 2013-08-27
EP1509253B1 (de) 2010-02-17
JP2005537785A (ja) 2005-12-15
US20110177556A1 (en) 2011-07-21
CN1671423A (zh) 2005-09-21
ATE458058T1 (de) 2010-03-15
CA2486918A1 (en) 2003-12-04
US7495090B2 (en) 2009-02-24
US20100297695A1 (en) 2010-11-25
IL165347A0 (en) 2006-01-15
DK1509253T3 (da) 2010-06-07

Similar Documents

Publication Publication Date Title
HK1076711A1 (en) Chimeric cd154
PT1240325E (pt) Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas
IL161769A0 (en) Anbtimicrobial polypeptides from pseudoplectania nigrella
WO2003000941A3 (en) Polypeptides having cellobiohydrolase i activity and polynucleotides encoding same
WO2005001064A3 (en) Polypeptides having alpha-amylase activity and polypeptides encoding same
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
WO2005069762A3 (en) Bacillus licheniformis chromosome
UA92580C2 (ru) Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение
AU2003291962A1 (en) Polypeptides having cellobiohydrolase ii activity and polynucleotides encoding same
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
AU2003238444A1 (en) The frog prince, a transposon vector for gene transfer in vertebrates
MX2022008955A (es) Variantes de mananasas y polinucleotidos que las codifican.
ZA202210127B (en) Codon optimized gla genes and uses thereof
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
NO20085086L (no) Fettsyresyntetase, polynukleotid som koder denne og anvendelse derav
IL165007A0 (en) Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
EP1572133A4 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
IL111608A0 (en) Tyrosinase-activator protein fusion enzyme
MXPA05011595A (es) Composiciones de spex y metodos de uso.
Wittenbrink et al. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the α2 domain
TW200801181A (en) GPR22 and methods relating thereto
DK1226236T3 (da) Polypeptider, der har glucanotransferase-aktivitet, og nucleinsyrer, som koder disse
WO2003025163A3 (fr) N-desoxyribosyltransferases de lactobacilies, sequences nucleotidiques correspondantes et leurs applications

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230518